Clinical Study
Safety and Efficacy of Glucomannan for Weight Loss in Overweight and Moderately Obese Adults
Table 1
Baseline demographic and clinical characteristics of study participants
.
| | Characteristic: (%) | Glucomannan | Control |
| | Gender | | | | Male | 3 (13%) | 4 (16.7%) | | Female | 20 (87%) | 20 (83.3%) | | Race/ethnic group | | | | White | 9 (39.1%) | 13 (54.2%) | | Black | 8 (34.8%) | 6 (25.0%) | | Hispanic | 4 (17.4%) | 5 (20.8%) | | Other | 2 (8.6%) | 0 (0%) | | Characteristic: mean (±SD) | | | | Age, years | 35.59 (12.21) | 41.59 (10.08) | | Height, ft/in | 5.42 (.41) | 5.50 (.30) | | Weight, kg | 83.27 (12.32) | 85.36 (12.41) | | Body mass index, kg/m2 | 30.70 (2.86) | 30.91 (3.28) | | Waist circumference, cm | 94.92 (10.25) | 96.73 (11.03) | | Hip circumference, cm | 112.99 (8.05) | 113.45 (7.41) | | Fat mass, kg | 32.93 (2.43) | 31.91 (2.37) | | Fat-free mass, kg | 51.99 (3.51) | 50.71 (3.61) | | Total cholesterol, mg/dL | 209.20 (41.82) | 204.29 (31.04) | | LDL cholesterol, mg/dL | 135.95 (33.41) | 129.76 (27.03) | | HDL cholesterol, mg/dL | 40.45 (8.49) | 53.24 (12.50) | | Triglycerides, mg/dL | 123.40 (61.26) | 106.90 (27.67) | | Fasting glucose, mg/dL | 87.05 (10.35) | 86.00 (11.29) |
|
|
